Business Context and Reporting Period
This Form 8-K Current Report from Decoy Therapeutics Inc. (DCOY) covers events occurring through March 31, 2026. The filing addresses the Company's status regarding Nasdaq listing compliance, specifically the Minimum Bid Price Requirement.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data point disclosed is the stock price:
- Stock Price: $7.47 per share (closing bid price on March 20, 2026).
Material Changes
The primary material event is the resolution of a Nasdaq delisting threat:
- Non-Compliance Notice: On December 31, 2025, Nasdaq notified the Company of non-compliance due to a closing bid price below $1.00 for 30 consecutive business days.
- Remedial Action: The Company implemented a reverse stock split effective March 6, 2026, with trading on a split-adjusted basis beginning March 9, 2026.
- Compliance Regained: The stock traded above $1.00 for 10 consecutive business days, closing at $7.47 on March 20, 2026. The Nasdaq Hearings Panel confirmed compliance on March 31, 2026.
Outlook, Risks, and Contingencies
Future Monitoring: The Company remains subject to a Mandatory Panel Monitor until March 31, 2027, to ensure continued compliance with Nasdaq listing standards.
Risks: Management highlights the risk of future non-compliance with Nasdaq listing standards. Failure to maintain compliance could result in delisting, leading to a loss of market value and liquidity. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of future performance and regulatory outcomes.
Investor Verification Checklist
- Verify the exact ratio of the reverse stock split implemented on March 6, 2026, to understand share count adjustments.
- Review the Company's most recent Form 10-K or 10-Q for cash runway and liquidity status, as this 8-K does not provide balance sheet data.
- Monitor the stock price to ensure it remains above the $1.00 threshold to avoid triggering the Mandatory Panel Monitor review again before March 31, 2027.
- Confirm the press release dated April 2, 2026 (Exhibit 99.1) for any additional operational updates not detailed in the 8-K text.